Bristol Myers Squibb says ZENBEXUS combo cuts multiple myeloma progression risk 51% in Phase 3 EXCALIBER-RRMM trial
Bitget2026/10/08 10:59Bristol Myers Squibb reported positive topline Phase 3 EXCALIBER-RRMM results for ZENBEXUS with daratumumab and dexamethasone in relapsed multiple myeloma. The regimen extended the time patients lived without disease worsening versus a standard-of-care comparator, supporting a stronger competitive profile. Detailed data are scheduled for presentation at the American Society of Hematology annual meeting; earlier response findings were presented at the International Myeloma Society meeting. ZENBEXUS has accelerated US clearance in this setting, with continued marketing dependent on confirmatory clinical benefit from trials such as EXCALIBER-RRMM. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202610080659BIZWIRE_USPR_____20261007_BW805859) on October 08, 2026, and is solely responsible for the information contained therein.
- Bristol Myers Squibb reported positive topline Phase 3 EXCALIBER-RRMM results for ZENBEXUS with daratumumab and dexamethasone in relapsed multiple myeloma.
- The regimen extended the time patients lived without disease worsening versus a standard-of-care comparator, supporting a stronger competitive profile.
- Detailed data are scheduled for presentation at the American Society of Hematology annual meeting; earlier response findings were presented at the International Myeloma Society meeting.
- ZENBEXUS has accelerated US clearance in this setting, with continued marketing dependent on confirmatory clinical benefit from trials such as EXCALIBER-RRMM.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
